CD200 upregulation in vascular endothelium surrounding cutaneous squamous cell carcinoma

JAMA Dermatology

Volumn 149, Issue 2, 2013, Pages 178-186

  Belkin, Daniel A ^a   Mitsui, Hiroshi ^b   Wang, Claire Q F ^b   Gonzalez, Juana ^b   Zhang, Shali ^c   Shah, Kejal R ^b   Coats, Israel ^b   Suàrez Fariñas, Mayte ^b   Krueger, James G ^b   Felsen, Diane ^a   Carucci, John A ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD200 ANTIGEN; CD200 RECEPTOR;

ACTINIC KERATOSIS; ARTICLE; CANCER PATIENT; CD200 GENE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; LASER MICRODISSECTION; MACROPHAGE; MYELOID DENDRITIC CELL; NATURAL KILLER CELL; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKIN CARCINOMA; T LYMPHOCYTE; TUMOR GROWTH; UPREGULATION; VASCULAR ENDOTHELIUM;

ACADEMIC MEDICAL CENTERS; ANTIGENS, CD; ANTIGENS, SURFACE; CARCINOMA, SQUAMOUS CELL; DENDRITIC CELLS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KILLER CELLS, NATURAL; LASER CAPTURE MICRODISSECTION; MACROPHAGES; MICROSCOPY, FLUORESCENCE; MOHS SURGERY; RECEPTORS, CELL SURFACE; SKIN; SKIN NEOPLASMS; T-LYMPHOCYTES; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; TUMOR MICROENVIRONMENT; UP-REGULATION;

EID: 84874265710     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.1609     Document Type: Article

References (41)

1. Weinberg AS, Ogle CA, Shim EK. Metastatic cutaneous squamous cell carcinoma: an update. Dermatol Surg. 2007;33(8):885-899.
2. Brantsch KD, Meisner C, Schönfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. 2008;9(8):713-720.
3. Lazarov M, Kubo Y, Cai T, et al. CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis. Nat Med. 2002;8(10):1105-1114.
4. Dajee M, Lazarov M, Zhang JY, et al. NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature. 2003;421(6923):639- 643.
5. Khavari PA. Modelling cancer in human skin tissue. Nat Rev Cancer. 2006;6(4): 270-280.
6. Wright GJ, Jones M, Puklavec MJ, Brown MH, Barclay AN. The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans. Immunology. 2001;102(2):173-179.
7. Wright GJ, Cherwinski H, Foster-Cuevas M, et al. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol. 2003;171(6):3034-3046.
8. Hoek RM, Ruuls SR, Murphy CA, et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science. 2000;290(5497):1768- 1771.
9. Rijkers ES, de Ruiter T, Baridi A, Veninga H, Hoek RM, Meyaard L. The inhibitory CD200R is differentially expressed on human and mouse T and B lymphocytes. Mol Immunol. 2008;45(4):1126-1135.
10. Meuth SG, Simon OJ, Grimm A, et al. CNS inflammation and neuronal degeneration is aggravated by impaired CD200-CD200R-mediated macrophage silencing. J Neuroimmunol. 2008;194(1-2):62-69.
11. Broderick C, Hoek RM, Forrester JV, Liversidge J, Sedgwick JD, Dick AD. Constitutive retinal CD200 expression regulates resident microglia and activation state of inflammatory cells during experimental autoimmune uveoretinitis. Am J Pathol. 2002;161(5):1669-1677.
12. Rosenblum MD, Yancey KB, Olasz EB, Truitt RL. CD200, a "no danger" signal for hair follicles. J Dermatol Sci. 2006;41(3):165-174.
13. Ohyama M, Terunuma A, Tock CL, et al. Characterization and isolation of stem cell-enriched human hair follicle bulge cells. J Clin Invest. 2006;116(1):249- 260.
14. Kretz-Rommel A, Qin F, Dakappagari N, et al. CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J Immunol. 2007;178(9):5595-5605.
15. Moreaux J, Veyrune JL, Reme T, De Vos J, Klein B. CD200: a putative therapeutic target in cancer. Biochem Biophys Res Commun. 2008;366(1):117-122.
16. Tonks A, Hills R, White P, et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia. 2007;21(3):566-568.
17. Petermann KB, Rozenberg GI, Zedek D, et al. CD200 is induced by ERK and is a potential therapeutic target in melanoma. J Clin Invest. 2007;117(12):3922- 3929.
18. Siva A, Xin H, Qin F, Oltean D, Bowdish KS, Kretz-Rommel A. Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. Cancer Immunol Immunother. 2008;57(7):987- 996.
19. Stumpfova M, Ratner D, Desciak EB, Eliezri YD, Owens DM. The immunosuppressive surface ligand CD200 augments the metastatic capacity of squamous cell carcinoma. Cancer Res. 2010;70(7):2962-2972.
20. Kube DM, Savci-Heijink CD, Lamblin AF, et al. Optimization of laser capture microdissection and RNA amplification for gene expression profiling of prostate cancer. BMC Mol Biol. 2007;8:25.
21. Fuentes-Duculan J, Suárez-Fariñas M, Zaba LC, et al. A subpopulation of CD163- positive macrophages is classically activated in psoriasis. J Invest Dermatol. 2010; 130(10):2412-2422.
22. Suárez-Fariñas M, Pellegrino M, Wittkowski KM, Magnasco MO. Harshlight: a "corrective make-up" program formicroarray chips. BMC Bioinformatics. 2005; 6:294.
23. Bluth MJ, Zaba LC, Moussai D, et al. Myeloid dendritic cells from human cutaneous squamous cell carcinoma are poor stimulators of T-cell proliferation. J Invest Dermatol. 2009;129(10):2451-2462.
24. Pettersen JS, Fuentes-Duculan J, Suárez-Fariñas M, et al. Tumor-associatedmacrophages in the cutaneous SCC microenvironment are heterogeneously activated. J Invest Dermatol. 2011;131(6):1322-1330.
25. Podgrabinska S, Braun P, Velasco P, Kloos B, Pepper MS, Skobe M. Molecular characterization of lymphatic endothelial cells. Proc Natl Acad Sci U S A. 2002; 99(25):16069-16074.
26. Franses JW, Baker AB, Chitalia VC, Edelman ER. Stromal endothelial cells directly influence cancer progression. Sci Transl Med. 2011;3(66):66ra5.
27. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9(4):239-252.
28. Barclay AN. Different reticular elements in rat lymphoid tissue identified by localization of Ia, Thy-1 and MRC OX 2 antigens. Immunology. 1981;44(4):727- 736.
29. Bukovský A, Presl J, Zidovský J, Mancal P. The localization of Thy-1.1, MRC OX 2 and Ia antigens in the rat ovary and fallopian tube. Immunology. 1983;48 (3):587-596.
30. Ko YC, Chien HF, Jiang-Shieh YF, et al. Endothelial CD200 is heterogeneously distributed, regulated and involved in immune cell-endothelium interactions. J Anat. 2009;214(1):183-195.
31. Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer. Cancer J. 2010;16(4):348-353.
32. Gorczynski RM, Cattral MS, Chen Z, et al. An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant that prolongs allo- and xenograft survival. J Immunol. 1999;163(3):1654-1660.
33. Taylor N, McConachie K, Calder C, et al. Enhanced tolerance to autoimmune uveitis in CD200-deficient mice correlates with a pronounced Th2 switch in response to antigen challenge. J Immunol. 2005;174(1):143-154.
34. Gorczynski RM, Yu K, Clark D. Receptor engagement on cells expressing a ligand for the tolerance-inducing molecule OX2 induces an immunoregulatory population that inhibits alloreactivity in vitro and in vivo. J Immunol. 2000;165(9): 4854-4860.
35. Koning N, van Eijk M, Pouwels W, et al. Expression of the inhibitory CD200 receptor is associated with alternative macrophage activation. J Innate Immun. 2010; 2(2):195-200.
36. Zhang S, Cherwinski H, Sedgwick JD, Phillips JH. Molecular mechanisms of CD200 inhibition of mast cell activation. J Immunol. 2004;173(11):6786-6793.
37. Jenmalm MC, Cherwinski H, Bowman EP, Phillips JH, Sedgwick JD. Regulation of myeloid cell function through the CD200 receptor. J Immunol. 2006;176 (1):191-199.
38. Fallarino F, Asselin-Paturel C, Vacca C, et al. Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. J Immunol. 2004;173(6):3748-3754.
39. Moussai D, Mitsui H, Pettersen JS, et al. The human cutaneous squamous cell carcinomamicroenvironment is characterized by increased lymphatic density and enhanced expression of macrophage-derived VEGF-C. J Invest Dermatol. 2011; 131(1):229-236.
40. Kretz-Rommel A, Qin F, Dakappagari N, Cofiell R, Faas SJ, Bowdish KS. Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. J Immunol. 2008;180(2):699-705.
41. Rygiel TP, Karnam G, Goverse G, et al. CD200-CD200R signaling suppresses anti-tumor responses independently of CD200 expression on the tumor. Oncogene. 2012;31(24):2979-2988.